EcoDrugPlus

Dihydropyrimidine Dehydrogenase B

Ensembl ID : ENSSMAG00000001180
Gene Symbol: DPYDB
2 Cross references
211 Possible Orthologues:

Discoidin Domain-Containing Receptor 2-Like

Ensembl ID : ENSSMAG00000009254
Gene Symbol: LOC118311602
2 Cross references
190 Possible Orthologues:

Dopamine Receptor D1b

Ensembl ID : ENSSMAG00000004335
Gene Symbol: DRD1B
3 Cross references
198 Possible Orthologues:

Dopamine Receptor D2a

Ensembl ID : ENSSMAG00000015553
Gene Symbol: DRD2A
1 Cross references
208 Possible Orthologues:

Dopamine Receptor D3

Ensembl ID : ENSSMAG00000013993
Gene Symbol: DRD3
3 Cross references
203 Possible Orthologues:

Dopamine Receptor D4a

Ensembl ID : ENSSMAG00000001390
Gene Symbol: DRD4A
2 Cross references
165 Possible Orthologues:

Dopamine Receptor D4b

Ensembl ID : ENSSMAG00000026244
Gene Symbol: DRD4B
2 Cross references
181 Possible Orthologues:

Echinoderm Microtubule-Associated Protein-Like 4

Ensembl ID : ENSSMAG00000006576
Gene Symbol: LOC118283741
2 Cross references
207 Possible Orthologues:

Ectonucleotide Pyrophosphatase/phosphodiesterase Family Member 2

Ensembl ID : ENSSMAG00000013835
Gene Symbol: LOC118291634
2 Cross references
226 Possible Orthologues:

Egl-9 Family Hypoxia Inducible Factor 1

Ensembl ID : ENSSMAG00000010675
Gene Symbol: EGLN1
1 Cross references
220 Possible Orthologues:

Egl-9 Family Hypoxia-Inducible Factor 2

Ensembl ID : ENSSMAG00000014356
Gene Symbol: EGLN2
2 Cross references
191 Possible Orthologues:

Egl-9 Family Hypoxia-Inducible Factor 3

Ensembl ID : ENSSMAG00000002860
Gene Symbol: EGLN3
1 Cross references
197 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).